in this issue
EnviroTech :: Regulatory
FDA Criticized for Negligence in Baxter Heparin Case
10:08 AM MST | March 3, 2008 | Deepti Ramesh
The U.S. FDA has been heavily criticized by Congress for not inspecting a plant in China that manufactures the active pharmaceutical ingredient (API) for heparin, a blood-thinning drug made by Baxter International (Deerfield, IL). Heparin has caused four deaths and had other harmful effects on a growing number of patients in the U.S. FDA confused the identity of the company that operates the Chinese API plant with that of another company with a similar name, when the API manufacturer applied for approval of its facility, reports say. The other company had been...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee